|
(ÁÖ)Á¦´º¿ø»çÀ̾𽺠|
³»¿ë°íÇüÁ¦ »ý»êÆÀÀå ä¿ë
¼¼Á¾½Ã ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
»ý»ê/»ý»ê°ü¸® |
10³â¡è |
05.21 |
|
|
|
¸®¼¸®½ºÅ׶óǻƽ½º(ÁÖ) |
¸®¼¸®½ºÅ׶óǻƽ½º »ç¾÷°³¹ß(BD) ¸ðÁý
¼¿ï °¼±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¼ö½Ãä¿ë |
3³â¡è |
05.12 |
05.03 |
|
|
(ÁÖ)´ë¿õ¹ÙÀÌ¿À |
[´ë¿õ¹ÙÀÌ¿À]¾È¼º°øÀå ÀǾàÇ° »ý»ê´ã´ç °æ·Â»ç¿ø ¸ðÁý
°æ±â ¾È¼º½Ã | ´ëÇÐ(2~3³â) Á¹¾÷ |
»ý»ê/»ý»ê°ü¸® |
2³â¡è |
05.10 |
04.29 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Multi-Channel Engagement Manager
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
7³â¡è |
ä¿ë½Ã |
04.29 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Market Access Lead, Cardiovascular and E
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
04.29 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Medical Advisor ä¿ë
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
04.29 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Sr. Regional Medical Advisor / Sr. Medic
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
4³â¡è |
ä¿ë½Ã |
04.30 |
|
|
(ÁÖ)´ë¿õ¹ÙÀÌ¿À |
[´ë¿õ¹ÙÀÌ¿À]ÀǾàÇ° Ç°Áú°ü¸® (QC) ´ã´çÀÚ °æ·Â»ç¿ø ¸ðÁý(¾È
°æ±â ¾È¼º½Ã | ´ëÇÐ(2~3³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
05.10 |
04.26 |
|
|
(ÁÖ)°í¹ÙÀÌ¿À·¦ |
[ÁÖ4.5ÀÏ]ÀÓ»óÆÀ ÆÀÀå ä¿ë
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
8³â¡è |
05.12 |
04.26 |
|
|
¹ÙÀÌÅ»¿¡¾îÄÚ¸®¾Æ |
ÀÇ·á±â±â ¿µ¾÷Á÷
´ëÀü ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
1³â¡è |
ä¿ë½Ã |
04.18 |
|
|
´º·ÎÇÍ ÁÖ½Äȸ»ç |
ÇØ¿Ü¿µ¾÷
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¹«¿ª/ÇØ¿Ü¿µ¾÷/Åë¹ø¿ª |
3³â¡è |
ä¿ë½Ã |
05.07 |
|
|
Novotech |
Pharmacovigilance Associate (Snr)_Korean Speaker Only
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
1³â¡è |
ä¿ë½Ã |
03.13 |
|
|
¼¼ºñ¾ÆÄÚ¸®¾Æ À¯ÇÑȸ»ç |
[Sebia KOrea Ltd.] Territory Manager
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
5³â¡è |
ä¿ë½Ã |
02.19 |
|
|
¾Ëº¸Á¨ ÄÚ¸®¾Æ ÁÖ½Äȸ»ç |
[¾Ëº¸Á¨ÄÚ¸®¾Æ] OPERATION QA Manager
°æ±â ȼº½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
5³â¡è |
ä¿ë½Ã |
02.20 |
|
|
Novotech |
[Novotech] Associate Clinical Data Manager Á¤±ÔÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
STAT/DM |
1³â¡è |
ä¿ë½Ã |
04.03 |
|